12:00 AM
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Bronchitol mannitol regulatory update

Pharmaxis said it was verbally notified that Australia's Pharmaceutical Benefits Advisory Committee (PBAC) recommended including cystic fibrosis (CF) drug Bronchitol mannitol for reimbursement on the Australian Pharmaceutical Benefits Scheme (PBS). Pharmaxis said Bronchitol will go before the Australian Pharmaceutical Benefits Pricing Authority (PBPA) to finalize the reimbursement. Pharmaxis filed...

Read the full 224 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >